Patent ID: 7455834

Claim:
A method of treating cancer in a mammal, comprising administering to said mammal an effective amount of WISP-1 antagonist to inhibit or reduce cancer cell growth or metastasis, wherein said antagonist comprises a chimeric anti-WISP-1 antibody which specifically binds to WISP-1 polypeptide and wherein said chimeric anti-WISP-1 antibody comprises a fragment from the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively which specifically binds to WISP-1 polypeptide, and further wherein said cancer is selected from the group consisting of pancreatic cancer, colon or colorectal cancer, breast cancer, lung cancer, and brain cancer.